Krish Patel
Krish Patel
Director, Lymphoma Program, Director, Hematologic Malignancies and Cellular Therapy
Dirección de correo verificada de - Página principal
Citado por
Citado por
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress
HS Kim, K Patel, K Muldoon-Jacobs, KS Bisht, N Aykin-Burns, ...
Cancer cell 17 (1), 41-52, 2010
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020
Use of convalescent plasma in hospitalized patients with COVID-19: case series
L Hegerova, TA Gooley, KA Sweerus, C Maree, N Bailey, M Bailey, ...
Blood, The Journal of the American Society of Hematology 136 (6), 759-762, 2020
CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region
P Nguyen, H Cui, KS Bisht, L Sun, K Patel, RS Lee, H Kugoh, M Oshimura, ...
Cancer research 68 (14), 5546-5551, 2008
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport
S Gollapudi, K Patel, V Jain, S Gupta
Cancer letters 62 (1), 69-75, 1992
Current and future treatment strategies in chronic lymphocytic leukemia
K Patel, JM Pagel
Journal of Hematology & Oncology 14 (1), 1-20, 2021
COVID-19 respiratory failure: targeting inflammation on VV-ECMO support
ME Hartman, RA Hernandez, K Patel, TE Wagner, T Trinh, AB Lipke, ...
Asaio Journal, 2020
Febrile neutropenia
K Patel, HJ West
JAMA oncology 3 (12), 1751-1751, 2017
Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma
V Bachanova, A Ghobadi, K Patel, JH Park, IW Flinn, P Shah, C Wong, ...
Blood 138, 823, 2021
Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers
ML Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ...
NEJM Evidence 1 (1), EVIDoa2100001, 2022
Mycosis fungoides: developments in incidence, treatment and survival
AE Kaufman, K Patel, K Goyal, D O'Leary, N Rubin, D Pearson, ...
Journal of the European Academy of Dermatology and Venereology 34 (10), 2288 …, 2020
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma
K Patel, AV Danilov, JM Pagel
Blood, The Journal of the American Society of Hematology 134 (19), 1573-1577, 2019
Use of the IL‐6R antagonist tocilizumab in hospitalized COVID‐19 patients
K Patel, TA Gooley, N Bailey, M Bailey, L Hegerova, A Batchelder, ...
Journal of internal medicine 289 (3), 430, 2021
Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell …
JN Allan, K Patel, AR Mato, WG Wierda, JP Ibarz, MY Choi, SM O'Brien, ...
Blood 134, 3041, 2019
NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B …
AR Mato, WG Wierda, WZ Ai, IW Flinn, M Tees, MR Patel, K Patel, ...
Blood 140 (Supplement 1), 2329-2332, 2022
The enrichment of an alkaliphilic biofilm consortia capable of the anaerobic degradation of isosaccharinic acid from cellulosic materials incubated within an anthropogenic …
CJ Charles, SP Rout, EJ Garratt, K Patel, AP Laws, PN Humphreys
FEMS microbiology ecology 91 (8), fiv085, 2015
Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia
AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ...
New England Journal of Medicine 389 (1), 33-44, 2023
The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model
MJ Gordon, A Kaempf, A Sitlinger, G Shouse, M Mei, DM Brander, ...
Clinical Cancer Research 27 (17), 4814-4824, 2021
Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin's lymphoma and chronic …
K Patel, JM Michot, AA Chanan-Khan, GA Salles, G Cartron, F Peyrade, ...
Blood 134, 4079, 2019
Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line …
P Strati, V Bachanova, A Goodman, JM Pagel, JE Castro, K Griffis, ...
Journal of Clinical Oncology 39 (15_suppl), 7541-7541, 2021
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20